-$0.32 EPS Expected for EXACT Sciences Co. (EXAS) This Quarter

Wall Street analysts forecast that EXACT Sciences Co. (NASDAQ:EXAS) will post ($0.32) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for EXACT Sciences’ earnings. The lowest EPS estimate is ($0.38) and the highest is ($0.27). EXACT Sciences reported earnings of ($0.27) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 18.5%. The business is scheduled to report its next quarterly earnings report on Tuesday, July 24th.

On average, analysts expect that EXACT Sciences will report full-year earnings of ($1.11) per share for the current fiscal year, with EPS estimates ranging from ($1.38) to ($0.89). For the next fiscal year, analysts anticipate that the firm will post earnings of ($0.28) per share, with EPS estimates ranging from ($0.71) to $0.25. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow EXACT Sciences.

EXACT Sciences (NASDAQ:EXAS) last issued its earnings results on Thursday, April 26th. The medical research company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.05. The company had revenue of $90.30 million for the quarter, compared to analyst estimates of $86.31 million. EXACT Sciences had a negative net margin of 38.61% and a negative return on equity of 20.92%. The business’s revenue was up 86.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.32) EPS.

Several brokerages have commented on EXAS. BidaskClub upgraded shares of EXACT Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, March 8th. BTIG Research restated a “buy” rating and set a $60.00 target price on shares of EXACT Sciences in a research report on Sunday, April 29th. Leerink Swann set a $67.00 target price on shares of EXACT Sciences and gave the stock a “buy” rating in a research report on Friday, February 9th. Benchmark lowered shares of EXACT Sciences from a “buy” rating to a “hold” rating in a research report on Friday, February 23rd. Finally, Goldman Sachs Group began coverage on shares of EXACT Sciences in a research report on Monday, January 29th. They set a “neutral” rating and a $51.00 target price on the stock. One analyst has rated the stock with a sell rating, five have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. EXACT Sciences has an average rating of “Buy” and an average target price of $53.84.

In related news, COO Maneesh Arora sold 12,352 shares of the business’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $42.34, for a total value of $522,983.68. Following the sale, the chief operating officer now directly owns 644,621 shares in the company, valued at approximately $27,293,253.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Graham Peter Lidgard sold 39,884 shares of the business’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $43.10, for a total transaction of $1,719,000.40. The disclosure for this sale can be found here. Insiders sold a total of 135,748 shares of company stock worth $6,082,759 over the last quarter. Insiders own 4.00% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the stock. Raymond James & Associates boosted its position in shares of EXACT Sciences by 1.2% in the 4th quarter. Raymond James & Associates now owns 98,777 shares of the medical research company’s stock worth $5,190,000 after buying an additional 1,168 shares in the last quarter. American International Group Inc. raised its stake in EXACT Sciences by 1.5% in the 4th quarter. American International Group Inc. now owns 79,238 shares of the medical research company’s stock valued at $4,163,000 after purchasing an additional 1,207 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. raised its stake in EXACT Sciences by 19.5% in the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 8,045 shares of the medical research company’s stock valued at $424,000 after purchasing an additional 1,315 shares during the last quarter. Sandy Spring Bank raised its stake in EXACT Sciences by 50.2% in the 1st quarter. Sandy Spring Bank now owns 4,672 shares of the medical research company’s stock valued at $188,000 after purchasing an additional 1,562 shares during the last quarter. Finally, M&T Bank Corp raised its stake in EXACT Sciences by 12.7% in the 1st quarter. M&T Bank Corp now owns 16,309 shares of the medical research company’s stock valued at $658,000 after purchasing an additional 1,839 shares during the last quarter. Institutional investors and hedge funds own 88.72% of the company’s stock.

Shares of EXACT Sciences opened at $52.85 on Tuesday, according to Marketbeat. The firm has a market cap of $6.26 billion, a price-to-earnings ratio of -53.38 and a beta of 0.86. EXACT Sciences has a one year low of $31.04 and a one year high of $63.60. The company has a debt-to-equity ratio of 0.71, a quick ratio of 14.86 and a current ratio of 15.30.

EXACT Sciences Company Profile

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Get a free copy of the Zacks research report on EXACT Sciences (EXAS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply